EUVIMEDEUVIMED entdecken
Crossref

Maintenence rituximab following induction in autoimmune cytopenias

Manoj P Rai iD, Eun-Ju Lee iD, James B Bussel iD

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18814 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Manoj P Rai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Autoimmune, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

About 50% of immune thrombocytopenia (ITP) patients respond to rituximab induction, but most relapse. The effectiveness of rituximab maintenance remains untested. This study included autoimmune cytopenia patients who had previously responded to rituximab induction but subsequently relapsed. After re‐induction, patients received rituximab maintenance regimen consisting of a single 375 mg/m 2 dose administered at 4 month intervals, with a maximum of 6 doses. Primary endpoints were duration of response and safety. Sixteen patients: ITP (9), autoimmune haemolytic anaemia (2), and Evans syndrome (5) received rituximab maintenance. 15/16 achieved complete response (CR); 8/15 CR + 1 partial reponse remain in remission. Median response: 43 months; estimated 5‐year relapse‐free >50%. Three developed hypogammaglobulinemia. Rituximab maintenance led to prolonged remissions in patients with autoimmune cytopenias who had previously responded to rituximab induction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Hemolytic, AutoimmuneThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicHumansRituximabTreatment OutcomeRetrospective StudiesRemission InductionRecurrence

Stichwörter der Autor:innen

Evans syndrome (ES)anti-CD20autoimmune haemolytic anaemia (AIHA)immune thrombocytopenia (ITP)outcomes

Substanzen

Rituximab

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Oregon Health and Science University, Portland, Oregon, USA.
  • Divisions of Hematology/Oncology and Pediatric Hematology-Oncology, Weill Cornell Medical College, New York, New York, USA.

ORCID-Profile: Manoj P Rai, Eun-Ju Lee, James B Bussel

Zitieren

APA

Rai, M. P., Lee, E. J., & Bussel, J. B. (2023). Maintenence rituximab following induction in autoimmune cytopenias. British Journal of Haematology. https://doi.org/10.1111/bjh.18814

Vancouver

Rai MP, Lee EJ, Bussel JB. Maintenence rituximab following induction in autoimmune cytopenias. British Journal of Haematology. 2023. doi:10.1111/bjh.18814

BibTeX
@article{Rai2023,
  author = {Rai, Manoj P and Lee, Eun-Ju and Bussel, James B},
  title = {Maintenence rituximab following induction in autoimmune cytopenias},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18814}
}
Kostenlos starten →